Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Dianthus Therapeutics (DNTH) EBT: 2017-2025

Historic EBT for Dianthus Therapeutics (DNTH) over the last 7 years, with Sep 2025 value amounting to -$36.6 million.

  • Dianthus Therapeutics' EBT fell 43.90% to -$36.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$125.5 million, marking a year-over-year decrease of 87.03%. This contributed to the annual value of -$84.5 million for FY2024, which is 94.65% down from last year.
  • According to the latest figures from Q3 2025, Dianthus Therapeutics' EBT is -$36.6 million, which was down 16.20% from -$31.5 million recorded in Q2 2025.
  • In the past 5 years, Dianthus Therapeutics' EBT ranged from a high of -$7.1 million in Q1 2023 and a low of -$36.6 million during Q3 2025.
  • In the last 3 years, Dianthus Therapeutics' EBT had a median value of -$17.5 million in 2024 and averaged -$20.5 million.
  • Data for Dianthus Therapeutics' EBT shows a maximum YoY slumped of 165.66% (in 2024) over the last 5 years.
  • Quarterly analysis of 4 years shows Dianthus Therapeutics' EBT stood at -$10.1 million in 2022, then declined by 4.57% to -$10.5 million in 2023, then slumped by 165.66% to -$27.9 million in 2024, then plummeted by 43.90% to -$36.6 million in 2025.
  • Its EBT was -$36.6 million in Q3 2025, compared to -$31.5 million in Q2 2025 and -$29.4 million in Q1 2025.